Crinetics Pharmaceuticals Appoints Alan Krasner, M.D., as Chief Medical Officer
18. Juni 2018 16:05 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, June 18, 2018 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel...
Crinetics Pharmaceuticals Completes $63.5 Million Series B Financing
13. März 2018 14:00 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, March 13, 2018 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc., a rare disease therapeutics company focused on endocrine disorders and endocrine-related cancers, today announced it...
Crinetics Pharmaceuticals Appoints Marc Wilson as Chief Financial Officer
04. Januar 2018 09:00 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Jan. 04, 2018 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc., a rare disease therapeutics company focused on endocrine disorders and endocrine-related cancers, today announced the...
Crinetics Pharmaceuticals to Present at J.P. Morgan Healthcare Conference
02. Januar 2018 09:00 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Jan. 02, 2018 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc., a rare disease therapeutics company focused on endocrine disorders and endocrine-related cancers, today announced that...
Crinetics Pharmaceuticals Initiates Phase 1 Study of Lead Candidate CRN00808 for Acromegaly
26. Oktober 2017 10:30 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Oct. 26, 2017 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc., a rare disease therapeutics company focused on endocrine disorders and endocrine-related cancers, today announced the...